How early have you been able to detect a response with CAR-T in patients with relapsed DLBCL?  

Responses to CAR-T cell therapy is generally very rapid. As seen in the ZUMA-1 trial median time to response was 30 days. Having said that there are patients in whom continued responses can be seen as late as 5-6 months post therapy, so patient who are in a PR at 1 month, it may be reasonable to jus...

Response to effector cellular therapies are fast due to the rapid in vivo expansion of these cells since they are armed with specificity and costimulation for rapid proliferation. The average time is a month from published clinical trials. Responses however are expected to continue to mature with ti...

The earliest reported time to response is approximately 30 days (although this is only because this is when most post infusional restaging is conventionally performed across trials). However, anecdotally based on personal experience with over 100 CAR T infusions across several tumor types/cellular c...